Benchmark Downgrades Nephros (NEPH) to Hold
- S&P 500 hits 2023 closing high as Powell strengthens peak rate bets
- Santa will continue to deliver - Stock Trader's Almanac
- 5 Tesla analysts weigh in as Tesla stock lags after Cybertruck updates
- Shares climb, dollar falls with Fed comments inspiring dovish bets
- Ulta Beauty lifts guidance after Q3 results beat estimates
Benchmark analyst Robert Wasserman downgraded Nephros (NASDAQ: NEPH) from Speculative Buy to Hold.
Shares of Nephros closed at $2.21 yesterday.
You May Also Be Interested In
- Goldman Sachs Downgrades AIB Group PLC (AIBG:ID) (AIBRF) to Neutral
- Piper Sandler Downgrades Texas Roadhouse (TXRH) to Neutral; 'More Balanced Risk-Reward'
- Jefferies Downgrades Ganfeng Lithium Group Co Ltd (002460:CH) to Underperform
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!